Another CCR5-targeting, viral-entry inhibiting drug, which is currently investigated in its efficiency to reduce COVID-19 symptoms, is the monoclonal IgG4 antibody leronlimab (CytoDyn, Vancouver, WA, Canada), formerly PRO140. This evidence concerns the gene CCR5 and COVID-19.